As AI progresses, it is important for all parties involved—researchers, developers, policymakers, and patients—to maintain continuous communication regarding its impact and potential. Through ongoing collaboration and the exchange of insights across disciplines, we can ensure that AI advancements in drug development are not only cutting-edge but also ethically sound and aligned with public health objectives.
This collaborative approach enables us to address challenges, share best practices, and develop frameworks that integrate AI innovations effectively. By using the collective expertise of industry leaders and fostering an environment of transparency and knowledge-sharing, we can better anticipate and mitigate risks, optimize AI applications, and drive forward the responsible development of life-saving drugs.
We are pleased to announce that LongeVC’s operating partner Artem Trotsyuk will participate in the public workshop on AI in drug and biological product development, which the FDA and CTTI are organizing on August 6 in Silver Spring and online.
Together with Hussein Ezzeldi from the FDA Center for Drug Evaluation and Research’s (CDER) Office of Biostatistics and Pharmacovigilance (OBPV), Luca Emili from InSilicoTrials, Michael Lingzhi Li from Harvard Business School, and Subha Madhavan from Pfizer, Artem will be a panelist speaking on Model Performance, Explainability, and Transparency.
If you’d like to meet with Artem during his trip to Silver Spring and Washington, connect with him on LinkedIn or send us an email at hq@longevc.com.
For more information about the event and online registration, please visit the website here.
This collaborative approach enables us to address challenges, share best practices, and develop frameworks that integrate AI innovations effectively. By using the collective expertise of industry leaders and fostering an environment of transparency and knowledge-sharing, we can better anticipate and mitigate risks, optimize AI applications, and drive forward the responsible development of life-saving drugs.
We are pleased to announce that LongeVC’s operating partner Artem Trotsyuk will participate in the public workshop on AI in drug and biological product development, which the FDA and CTTI are organizing on August 6 in Silver Spring and online.
Together with Hussein Ezzeldi from the FDA Center for Drug Evaluation and Research’s (CDER) Office of Biostatistics and Pharmacovigilance (OBPV), Luca Emili from InSilicoTrials, Michael Lingzhi Li from Harvard Business School, and Subha Madhavan from Pfizer, Artem will be a panelist speaking on Model Performance, Explainability, and Transparency.
If you’d like to meet with Artem during his trip to Silver Spring and Washington, connect with him on LinkedIn or send us an email at hq@longevc.com.
For more information about the event and online registration, please visit the website here.